Verekitug

Phase 2Small molecule

UUpstream Bio Inc.

Verekitug is one of 61 small molecule programs targeting Asthma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaRecruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

AsthmaPhase 2

Recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

1 2

Verekitug

UUpstream Bio Inc.

Phase 2

2 3

Paracetamol

GSK

Preclinical

1 4

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 5

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 6

Lexapro

SShirley Ryan AbilityLab

Preclinical

1 7

Biological Drug

UUniversitaire Ziekenhuizen KU Leuven

Preclinical

1 8

Guanidine Hydrochloride

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Rhinovirus

UUniversity of Virginia

Preclinical

2 10

FP/SAL

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Asthma

NCT06966479

Q4 2027

Phase 2Active, not recruiting

Chronic Obstructive Pulmonary Disease

NCT06981078

Clinical

Trials by Indication[1]

Asthma2 trials

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

Recruiting·UUpstream Bio Inc.·Phase 2·NCT06966479·436 enrolled

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

Active, not recruiting·UUpstream Bio Inc.·Phase 2·NCT06196879·479 enrolled

Chronic Rhinosinusitis With Nasal Polyps1 trial

A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps on a Background of Nasal Corticosteroids (VIBRANT)

Completed·UUpstream Bio Inc.·Phase 2·NCT06164704·81 enrolled

Chronic Obstructive Pulmonary Disease1 trial

A Phase 2b Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess Efficacy and Safety of Verekitug (UPB-101) in Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Active, not recruiting·UUpstream Bio Inc.·Phase 2·NCT06981078·666 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Verekitug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Verekitug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Verekitug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Upstream Bio Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUpstream Bio Inc.

Verekitug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Trials by Indication[1]

Asthma2 trials

Chronic Rhinosinusitis With Nasal Polyps1 trial

Chronic Obstructive Pulmonary Disease1 trial

References

Drug Info

Quick Facts

Related News